Lighthouse International is testing the Argus II Retinal Implant, in an FDA-approved trial for people who are blind or severely vision-impaired due to Retinitis Pigmentosa. Lighthouse is one of six sites in the US testing the technology.

The Argus II communicates with the visual system via a 60-electode grid as thin as human hair that is surgically implanted and attached to the retina. Electrodes transmit information sent from an external video camera that is mounted on a pair of eyeglasses worn by the participant. The new technology is assistive by allowing people who are blind to gain rudimentary vision using an artificial retina that presents the camera imagery through the eye and brain’s natural neural pathways.

Learn More:

Feature Article
Research Trial of Artificial Retina Lets the Light Shine In

Press Release
Lighthouse International Tests Argus II Retinal Prosthesis System on First Patient in New York City

 

 

Like us on Facebook   Follow us on Twitter   Watch us on Youtube   Email   Visit our Flickr